%0 Journal Article %A KAREL SMETANA, JR. %A DANIEL ROSEL %A JAN BRÁBEK %T Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality %D 2020 %R 10.21873/invivo.12135 %J In Vivo %P 3027-3028 %V 34 %N 5 %X The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity. %U https://iv.iiarjournals.org/content/invivo/34/5/3027.full.pdf